JPRN-UMIN000018754已完成未知
Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic control - Dapagliflozin effectiveness on the vascular endothelial function and glycemic control (DEFENCE study)
Japan Society for Patient Report Outcome0 个研究点目标入组 80 人开始时间: 2015年8月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who fall into any of the following criteria are excluded from participating in the study. 1. Type 1 diabetes or secondary diabetes 2. Had used SGLT2 inhibitors, GLP-1 agonists, or insulin 12 weeks before providing their consent 3. Had used a dose of metformin exceeding 750mg per day 12 weeks before providing their consent 4. Had started taking angiotensin-converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor antagonist (ARB), HMG-CoA reductase inhibitor (statin), or antiplatelet drugs, or had their medication dose changed (including reducing the dose) 12 weeks before providing their consent 5. Patients who have a severe infection, have had or are about to have surgery, or are suffering from a serious trauma 6. With a medical history of myocardial infarction, angina, stroke or cerebral infarction 7. With atrial (chronic) fibrillation, frequent supraventricular or ventricular ectopy 8. With a moderate or severe level of cardiac insufficiency (patients with class III or more as classified by the NYHA/New York Heart Association) 9. Ankle Brachial Pressure Index (ABI)< 0.9 10. Serious liver or renal functional failure (serum creatinine 1.3mg/dL or greater, or eGFR< 45mL/min/1.73 square meters) 11. Unstable blood pressure or lipid abnormalities within 12 weeks before providing their consent 12. Addicted to alcohol or drugs 13. Patients who are pregnant or breastfeeding, or who may be, or plan to be, pregnant 14. Dehydrated (abnormal test results of hematocrit and BUN values, and complaint of symptoms of dehydration) 15. Using diuretics 16. Urinary tract or genital infections within 12 weeks before providing their consent 17. With a past history of hypersensitivity to the study drug 18. At risks of ketoacidosis, diabetic coma or precoma 19. Other conditions considered to be unsuitable by the attending physician
研究者
相似试验
尚未招募
2 期
Dapagliflozin in Pulmonary Arterial HypertensioPulmonary arterial hypertension.Primary pulmonary hypertensionI27. 0IRCT20200209046427N2Shahid Beheshti University of Medical Sciences100
已完成
2 期
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)Renal Insufficiency, ChronicNCT04930549University Hospital, Rouen32
进行中（未招募）
1 期
Effect of Empagliflozin on Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 DiabetesPatients with Type 2 diabetes mellitusEUCTR2016-000172-19-DERWTH Aachen University for the Medical Faculty, represented by Center for Transitional & Clinical Research Aachen (CTC-A44
已完成
3 期
Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium ContentDiabetes Mellitus Type 2NCT02383238University of Erlangen-Nürnberg Medical School59
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.EUCTR2013-000239-28-NLAstraZeneca AB17,150